Compare Natera Inc. Common Stock (NTRA) vs Impinj Inc (PI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Impinj Inc — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Impinj Inc trades at $189.45 (market cap $5.60B). The key difference: Natera Inc. Common Stock is far larger — about 10.2× Impinj Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Impinj Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Impinj Inc for 22 Days on average.
| NTRA | PI | |
|---|---|---|
Market Cap | $57.03B | $5.60B |
Volume | 1,131,157 | 39,355 |
Sector | Health | Technology |
52-Week High | $425.64 | $241.91 |
52-Week Low | $179.42 | $91.34 |
Typical Hold Time | 0 Days | 22 Days |
Enterprise Value | $56.18B | $5.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Impinj (PI) trades at $183.26, down 3.56% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 results with EPS of $0.86 beating estimates, though it operates at a net loss margin of -7.26%. Recent news highlights CEO optimism about growth in RFID tracking markets and upcoming Q3 earnings.
Outlook remains mixed: analyst consensus is bullish (73% buy ratings) with a $178.83 price target, but high valuation multiples and persistent losses pose risks. Key catalysts include Q3 earnings and execution in retail and logistics segments, while competition and margin pressure are concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
